| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
6-Aminonicotinamide targets NADP+-dependent enzymes, particularly glucose-6-phosphate dehydrogenase (G6PD) with a Ki of 0.46 μM. It is a competitive inhibitor of G6PD, which is a key enzyme in the pentose phosphate pathway. By inhibiting G6PD, it depletes cellular NADPH, leading to oxidative stress and apoptosis in tumor cells.
|
|---|---|
| ln Vitro |
6-Aminonicotinamide (100 nM; 7 days) dramatically lowers AR+ in CRPC-derived C4-2 and 22Rv1 cell models, human AR+, and hormone-sensitive prostate cancer cell lines LNCaP and LAPC4. Basal and R1881-mediated ROS levels are increased by 6-aminonicotinamide (100 nM ± 10 nM R1881) for three days, suggesting that 6-aminonicotinamide is obstructing the cell's antioxidant defenses. In C4-2 cells, 6-aminonicotinamide can also raise ROS levels [3].
6-Aminonicotinamide is a potent inhibitor of G6PD with a Ki of 0.46 μM. It induces apoptosis in tumor cells. Its in vitro activity is assessed by measuring the inhibition of G6PD enzyme activity in cell lysates or by measuring the induction of apoptosis in tumor cell lines. |
| ln Vivo |
6-Aminonicotinamide (20 mg/kg; intraperitoneally; stimulation time; days 1, 10, or 11 and 21) by itself caused a little but notable halt in tumor growth (4.3 +/- 0.8 days). Treatment with 6-Aminonicotinamide and radiation caused a tumor growth delay of 57.0+/-3.8 days in a CD8F1 breast tumor model [4].
6-Aminonicotinamide is clinically used in disseminated neoplastic disease. It induces apoptosis in tumor cells. It also acts as a 6-phosphogluconate dehydrogenase inhibitor and aids in the treatment of psoriasis. |
| Enzyme Assay |
The inhibition of G6PD by 6-Aminonicotinamide can be assessed using an in vitro enzyme assay. G6PD enzyme is incubated with its substrate, glucose-6-phosphate, and NADP+ in the presence of varying concentrations of the inhibitor. The production of NADPH is measured spectrophotometrically, and the Ki is determined.
|
| Cell Assay |
6-Aminonicotinamide is used in cell culture to study the effects of G6PD inhibition on cellular metabolism and apoptosis. Tumor cells are treated with the compound, and the induction of apoptosis is measured by caspase-3/7 activity or by Annexin V staining. The depletion of NADPH and the increase in oxidative stress are also measured.
|
| Animal Protocol |
6-Aminonicotinamide is used in animal models of cancer to study its antitumor activity. The compound is administered to tumor-bearing animals, and tumor growth is monitored. The effect on G6PD activity and NADPH levels in tumor tissue is also assessed.
|
| ADME/Pharmacokinetics |
6-Aminonicotinamide has a molecular weight of 137.14 g/mol and a molecular formula of C6H7N3O. It is a solid that is insoluble in water. The compound should be stored at room temperature in a cool and dark place.
|
| Toxicity/Toxicokinetics |
Toxicological data for 6-Aminonicotinamide are not extensively detailed. It is a potent antimetabolite and should be handled with care. The compound is not intended for human or veterinary use except in clinical settings. Standard laboratory safety precautions, including the use of personal protective equipment (PPE), should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
6-Aminonicotinamide is a white crystalline solid. (NTP, 1992)
6-Aminonicotinamide is a monocarboxylic acid amide formed by the condensation of the carboxyl group and ammonia of 6-aminonicotinic acid. It is an inhibitor of the NADP+-dependent enzyme 6-phosphoglucuronide dehydrogenase, interfering with glycolysis, leading to ATP depletion, and synergistically killing cancer cells with DNA-crosslinking chemotherapeutic drugs such as cisplatin. It has teratogenic, antimetabolitic, and EC 1.1.1.44 (NADP+-dependent decarboxylphosphoglucuronide dehydrogenase) inhibitory effects. It is an aminopyridine compound, a primary amino compound, and a monocarboxylic acid amide. It is functionally related to 6-aminonicotinic acid. 6-Aminonicotinamide is a synthetic analog and a cytotoxic nicotinamide antagonist. 6-Aminonicotinamide forms aberrant NAD (a ubiquitous metabolic pathway coenzyme) analogs, thereby inhibiting the activity of NAD-dependent enzymes associated with ATP production. 6-Aminonicotinamide can impair cartilage formation, may have teratogenic effects, and enhance the effects of radiation therapy and cisplatin treatment (forming platinum-DNA complexes). (NCI04) A teratogenic vitamin antagonist. 6-Aminonicotinamide is a potent antimetabolite of nicotinamide and a competitive inhibitor of G6PD. It induces apoptosis in tumor cells and is clinically used in disseminated neoplastic disease. It also aids in the treatment of psoriasis. The compound is a valuable tool for studying the pentose phosphate pathway and its role in cancer and other diseases. |
| Molecular Formula |
C6H7N3O
|
|---|---|
| Molecular Weight |
137.14
|
| Exact Mass |
137.058
|
| CAS # |
329-89-5
|
| PubChem CID |
9500
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
381.6±27.0 °C at 760 mmHg
|
| Melting Point |
473 to 478 °F (NTP, 1992)
|
| Flash Point |
184.6±23.7 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.644
|
| LogP |
0.41
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
137
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=NC=C1C(=O)N)N
|
| InChi Key |
ZLWYEPMDOUQDBW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H7N3O/c7-5-2-1-4(3-9-5)6(8)10/h1-3H,(H2,7,9)(H2,8,10)
|
| Chemical Name |
6-aminopyridine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (729.18 mM)
H2O: 11.11 mg/mL (81.01 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (18.23 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (18.23 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (18.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 4 mg/mL (29.17 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2918 mL | 36.4591 mL | 72.9182 mL | |
| 5 mM | 1.4584 mL | 7.2918 mL | 14.5836 mL | |
| 10 mM | 0.7292 mL | 3.6459 mL | 7.2918 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
